Latest Headlines

Latest Headlines

Setbacks tarnish Bristol-Myers' 'string of pearls'

Bristol-Myers Squibb's "string of pearls" is starting to look a little dull to investors.

Vertex dumps one hep C dud, races ahead with second all-oral hope

A little more than a year after Vertex licensed in a pair of "nucs" from Alios BioPharma in a high-stakes bid to develop an oral, interferon-free approach to hepatitis C, Vertex is jettisoning one as a dud while racing ahead with the second into a mid-stage study slated to begin in a matter of weeks.

Bankers tally torrid pace for biotech M&A as hungry suitors pounce

Venture deals may be well off the pace set in 2011, but even a casual observer of the biotech industry could tell you that M&A is way up. Now Credit Suisse has stepped up with a new set of figures to back up the trend, noting that we haven't seen these kinds of numbers since Roche bought out Genentech for $46.7 billion in 2008.

Analyst reads last rites after heart failure scuttles Bristol hep C study

A safety crisis has forced Bristol-Myers Squibb to slam the brakes on a mid-stage study of a hepatitis C drug, threatening the future of a program that was at the heart of a recent $2.5 billion buyout.

Hep C drug deal frenzy can't be slowed by growing doubts

At the BIO CEO & Investor Conference in New York yesterday, Achillion CEO Michael Kishbauch wrapped up his remarks on the biotech's hepatitis C programs by making it clear that he was angling for

Gilead shares surge as hep C drug scores a cure for big patient population

Gilead Sciences ($GILD) received its first bonus from the monster $10.8 billion deal to acquire Pharmasset ($VRUS) after CSO Norbert Bischofberger told analysts yesterday evening that PSI-7977

Vertex outlines its survival plan for next-gen hep C combo

At the beginning of 2011, Vertex ($VRTX) was basking in the limelight of blockbuster success. Its hepatitis C drug was headed for approval, offering a game-changing approach to the disease, and was

Bristol-Myers reports interferon-free cures in small PhII hep C study

While Bristol-Myers Squibb ($BMY) was dealt a setback today on the diabetes front, investigators were reporting progress with a new combination approach to hepatitis C that's raising hopes for an

Bristol CEO touts successful biopharma blitz after big hep C play

Bristol-Myers Squibb ($BMY) mounted an enviable makeover from a diversified company to a biopharma force over the past several years, with the famed "String of Pearls" strategy advanced to buy

JPM kicks off with fevered focus on the next big biotech deal

The news of the Bristol-Myers/Inhibitex deal couldn't have been better timed. With the biotech world converging on San Francisco today for the annual JP Morgan confab, there's nothing like a